KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $194.9 million.

  • Vertex Pharmaceuticals' Share-based Compensation rose 5.58% to $194.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $696.1 million, marking a year-over-year decrease of 5.84%. This contributed to the annual value of $698.5 million for FY2024, which is 20.18% up from last year.
  • Vertex Pharmaceuticals' Share-based Compensation amounted to $194.9 million in Q3 2025, which was up 16.50% from $167.3 million recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Share-based Compensation peaked at $208.6 million during Q4 2023, and registered a low of $103.0 million during Q3 2021.
  • In the last 3 years, Vertex Pharmaceuticals' Share-based Compensation had a median value of $167.3 million in 2025 and averaged $164.4 million.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Share-based Compensation soared by 87.09% in 2023, and later dropped by 19.56% in 2024.
  • Vertex Pharmaceuticals' Share-based Compensation (Quarterly) stood at $118.6 million in 2021, then decreased by 5.99% to $111.5 million in 2022, then skyrocketed by 87.09% to $208.6 million in 2023, then declined by 19.56% to $167.8 million in 2024, then grew by 5.58% to $194.9 million in 2025.
  • Its Share-based Compensation was $194.9 million in Q3 2025, compared to $167.3 million in Q2 2025 and $166.1 million in Q1 2025.